PharmaVentures appoints senior director

Paul Phull will develop corporate advisory business

PharmaVentures, based in Oxford, UK, has hired Paul Phull as senior director to develop its corporate advisory business.

PharmaVentures is an international corporate advisory firm supporting its clients’ growth ambitions through licensing, joint ventures and M&A in the healthcare industry. The company works for a variety of clients from start-ups to global pharmaceutical corporations, their advisers, investment companies and government bodies.

Phull joins the company from Sinclair Pharma, a specialist pharmaceutical company in the UK, where he was responsible for the development of the international business. He has significant deal making and corporate transaction experience with a broad range of companies in Europe, US, Japan, India and Asia in a number of therapeutic areas.

You may also like

Manufacturing

Viatris to cut 10% of its global workforce after Indian plant fire

Viatris has lowered its profit outlook for 2026 after a fire in February shut down a key plant in Nashik, India. Despite this, the company reported stronger-than-expected revenue and announced a restructuring plan
Finance

Heligan Group report: UK healthcare M&A remains resilient

A new report from the investment group has highlighted the healthcare field as being a "defensive, structurally supported sector"
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Procurement as a strategic business enabler

How Alkermes unlocked $30m in project cost savings with JAGGAER
Finance

Axol Bioscience expands ophthalmology portfolio with acquisition of Newcells Biotech business

Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, strengthening its iPSC-derived retinal organoid and RPE model offerings
Finance

Gilead Sciences to acquire Arcellx in $7.8 billion deal to advance Anito-cel

Gilead Sciences has agreed to acquire Arcellx for $7.8bn, gaining full control of investigational CAR T therapy anito-cel following FDA acceptance of its BLA for relapsed/refractory multiple myeloma
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Lario Therapeutics secures $2.4m from MJFF and Wellcome to expand CNS calcium channel programmes

The company has been awarded $2.4m in grant funding from The Michael J. Fox Foundation for Parkinson's Research and Wellcome to advance its neuronal calcium channel platform into Parkinson's disease and post-traumatic stress disorder
Research & Development

Horizon Europe 2025 grant backs Phase II trial of HER-096 for Parkinson’s disease

Herantis Pharma has secured selection for €8m in non-dilutive funding under Horizon Europe to advance a Phase II proof-of-concept study of its subcutaneously delivered Parkinson’s therapy candidate HER-096
Subscribe now